Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
on May 8th, you posted that Germany brought in 50% of the revenue, which is it? Thanks.
pearsby, you are spreading misinformation again, as usual. All that you have to do is read JoelY's post below for the correct information that was published by CTSO on May 24, 2017. Also as JoelY stated, if data is overwhelming, the trial can be ended early.
• REFRESH 2 is expected to be similar in design to REFRESH 1, but with a more focused target population that accounts for more than half of all complex cardiac surgeries that demonstrated the
highest levels of pfHb and are at greatest risk for organ injury
• Preliminary trial design, pending discussions with the FDA:
– Plan to start with core sites from REFRESH 1
– 300-500 patient, 30-40 center randomized, controlled PMA trial
– Primary clinical and cost-effectiveness endpoints: Progression to acute kidney injury (AKI),
incidence of stroke, time on mechanical ventilation, hemodynamic stability, days in the ICU
– 2 year expected duration at 0.5 patients/month/site
– $10-12M cost spread out over 3 years – potential for strategic partner support
– Targeting 1H 2019 enrolled, 2H 2019 data, 2020 targeted approval
fact check on pearsby. The share value is $3.95, not .16. That means that we are on the Nasdaq, not an OTC penny stock when it truly was .16, and .08 years ago. That is after 5 years, not 9 years as you state, check the company website for verification. The truth is that you don't know how far off the beads are from being used for a cancer indication, it could already be happening. With the brilliant company EU approval as a cytokine reducer, it can be used for any cytokine reducing treatment, including cytokine storm from CAR T cell treatments. Of course that would be in the 42 countries that it is approrved for, not the US yet.
since most of you paulsby aliases are using the same cut and paste message, I am inclined to believe that it is just paulsby posting the same "do away with Chan" message over and over. Although you deny being him, paulsby has patterns that are easy to discern after you see them so many times.
A good article bertha. What a great hire he is from Dr. Chan. It speaks volumes that Dr. June, this pioneer and leader in T-cell research came to work for Cytosorbents.
cars100cars, where did you see the information regarding WHO giving CTSO $4.6 million for marketing,etc. Thanks.
paulsby, please explain why you would pass up sales for cancer, cardio, etc. why we proceed to get FDA approval for sepsis in the USA. By the way, you may not know it but we are already eradicating sepsis in a very large portion of the world.
thank you for your response, I believe that there is also a huge potential with the military with the anti fungal research and the universal donor/hemodefend products.
psuforlife, a question. Since we are not FDA approved for the USA, how would this work? Thanks.
paulsby, bertha and I are not the same, you know this. I do admire the time that he puts in to keep us informed. I see no pumping on this board, is that what you call individuals posting facts? You on the other hand have been caught on yahoo with screen savers posting under multiple aliases. You are even resurrecting some of your old ones now along with newly minted within the last week. You have no credibility, you can not have a good agenda posting under multiple aliases.
paulsby, I don't mind someone informing me of negative information, but it should be based on factual information. You state that Fresenius has been an exclusive distributor with CTSO in 4 countries for 2 plus years? Here is the PR dated June 1, 2017, less than 1 year ago. MONMOUTH JUNCTION, N.J., June 1, 2016 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood purification cartridge to prevent or treat deadly inflammation and organ failure in critically-ill and cardiac surgery patients around the world, announced that Fresenius Medical Care (FMC), its strategic partner for acute care indications in France, Poland, Sweden, Denmark, Finland, and Norway, has officially initiated its CytoSorb® sales efforts.
Everyone knows that all of these negative posts are in fact just you, one person, trying to drive the sales price down, so that you can restock for your day trading.
Wow paulsby, looks like you are stating your years in dog/cat years. We, not you, have been waiting less than 5 human years since product sales began in Q32012. Looks like your other numbers are in dog/cat years also and they sure aren't what Dr. Chan is predicting.
CytoSorbents and University of Pennsylvania Vet School Collaborate to Expand CytoSorb(R) Research in Cancer Immunotherapy. MONMOUTH JUNCTION, NJ--(Marketwired - Feb 10, 2014) - CytoSorbents Corporation ( OTCQB : CTSO ), a critical care immunotherapy company, and the University of Pennsylvania School of Veterinary Medicine ("Penn Vet") announced its research collaboration to investigate the use of CytoSorb®, a unique cytokine reduction filter for blood, as a potential new approach in cancer immunotherapy.
The research collaboration is initially focused on the treatment of cancer cachexia -- a progressive wasting syndrome characterized by rapid weight loss, anorexia, and physical debilitation that significantly contributes to death in the majority of animal and human cancer patients. Cancer cachexia is a systemic inflammatory condition, driven by excessive pro-inflammatory cytokines and other factors, that cripples the patient's physical and immunologic reserve to fight cancer. Despite afflicting millions of patients worldwide each year, there are no effective approved treatments for cancer cachexia, with only symptomatic treatments, such as medical marijuana, available.
CytoSorb® blood purification may stop or reverse cancer cachexia through broad reduction of cytokines and other inflammatory mediators. For example, CytoSorb® efficiently removes TNF-a (originally called "cachectin" or "cachexin" when first isolated in cancer cachexia patients) and other major pro-inflammatory cytokines including IL-1, IL-6, and gamma interferon that can cause cachexia. This broad immunotherapy approach may lead to improved clinical outcomes while reducing patient suffering.
The collaboration will also explore the use of CytoSorb® as a primary immunotherapy to treat cancer, or in synergy with more traditional chemotherapy or immunotherapy agents. Cancer cells have evolved ways to proliferate while confusing and evading the immune response. Many of these mechanisms rely on immunologic messages relayed by cytokines and other soluble factors that CytoSorb® has the potential to remove. In doing so, CytoSorb® may help to restore the ability of the immune system to attack cancer cells.
Dr. Phillip Chan, MD, PhD, Chief Executive Officer of CytoSorbents, stated, "Demonstrating the potential benefit of CytoSorb® therapy in animals will provide the data to begin evaluating the therapy in human cancer patients in the U.S. and Europe. CytoSorb® is approved in the European Union with a broad indication for use, allowing it to be used in any clinical situation where cytokines are elevated, including the potential treatment today of cancer related issues such as cancer cachexia. Because of this, any positive data from this collaboration could be translated to human studies relatively quickly."
Dr. Erika Krick, VMD, Assistant Professor of Oncology of Penn Vet with strong research interests in cancer cachexia, commented, "Clinical signs of cancer cachexia are seen most commonly in our feline cancer patients and can significantly impact the patient's and caregiver's quality of life. We are excited about the opportunity to evaluate CytoSorb® as a therapy specifically directed towards the cancer cachexia syndrome, in combination with standard cancer treatments."
Dr. Chan continued, "In addition to this focus on cancer, we will also be collaborating with Penn Vet on the treatment of animals with sepsis, pancreatitis, and other critical illnesses. We hope to demonstrate similar benefits in animals as seen in humans with life-threatening conditions. We are pleased to be working with Penn Vet in cancer and critical care research."
Dr. Deborah Silverstein, DVM, Associate Professor of Penn Vet, and co-author of the text "Small Animal Critical Care Medicine," stated, "The ability to remove excessive, and often damaging, inflammatory mediators has the potential to greatly reduce morbidity and mortality in critically ill small animals that suffer from severe systemic inflammation or sepsis. We are eager to begin enrolling severely ill dogs soon and seek additional resources to expand the study."
About University of Pennsylvania School of Veterinary Medicine ("Penn Vet")
Penn Vet is a global leader in veterinary medicine education, research, and clinical care. Founded in 1884, Penn Vet is the only veterinary school developed in association with a medical school. The school is a proud member of the One Health Initiative, linking human, animal, and environmental health.
To help with a cure for cancer would be the Holy Grail, perhaps it is nearer at hand then pearsby finding his moral compass.
Bertha, I agree that great strides may be coming with Dr. Carl June joining the CTSO advisory board. I am attaching the video link from the company about him. https://vimeo.com/67745009. It can send chills up your spine, Dr. June is The Man in the field of cancer therapy.
Thank you debitsandcredits for a well thought out and researched presentation. I am very visual and love charts, they make it much easier to understand what is occurring.
Everything that orangecat stated can be proved, paulsby. "CytoSorb-XL is a new, state-of-the-art porous polymer bead technology that combines lipopolysaccharide (LPS) endotoxin removal with the robust cytokine, toxin, and inflammatory mediator reduction achieved by CytoSorb®. CytoSorb-XL and its novel endotoxin binding chemistry is the subject of a broad composition of matter patent application, intended to protect the technology worldwide for the next two decades.In a head-to-head comparison with the leading endotoxin adsorber, Toraymyxin™ (Toray, Japan), CytoSorb-XL matched the level of endotoxin reduction in an in vitro plasma recirculation system on a comparable volume basis. CytoSorb-XL is expected to eliminate the need for stand-alone endotoxin specific filters by offering superior performance in the removal of not just endotoxin, but a much broader array of inflammatory mediators that drive uncontrolled deadly inflammation, organ failure, and death in sepsis."
Cytosorb XL basically knocked Spectal out of the water when it was announced. Oh yes, you pushed Spectral on this board hard for years, now it is 39 cents. The main point on Cytosorb XL is that it pushes out the patents another 20 years while you used to whine that our patents were going to expire. Oh yes, as far as I know, you dont' own any CTSO, you are waiting to buy in at $3.40 or so.
One thing you must know is that pearsby has perhaps a dozen aliases. He had been caught several times by me and others on the board. He was even caught with a pumper alias to go with his mostly negative basher aliases. He also criticizes the company on it's Facebook page and on yahoo conversations. He is either trying to swing day trades his way or shorting, probably both.
The sales growth is not anemic paulsby, any company would love to have 20% sales growth per quarter, which equates to 100% per year.
What capital raise would that be paulsby? We just had one and it is back near the pre raise price. The missing data you are writing about could be released this afternoon.
A good article, also he does not take into consideration of the "shots on goal" of cancer, Hemodefend, universal donor, anti-fungal, etc.
htcblue, how can you say nothing positive?Awarded $1M Phase II SBIR Contract by U.S. Department of Defense to Advance Fungal Mycotoxin Blood Purification, Phase I last year. New recent patent protections, additional terotories added, Refresh I trial complete, Refresh II to begin soon, renowned Dr. June added to staff for possible cancer applications, new sales records set for each quarter for several years now, basically a doubling of sales yearly, VetResQ product added, Fresenius partnership expanded, reimbursement in Germany added. It goes on and on.
Interesting older article bertha, Cytosorb could be used to treat inflammatory breast cancer and rheumatoid arthritis.
https://www.ncbi.nlm.nih.gov/pubmed/22027148
I feel that something will happen very quickly with Dr. Carl H. June being named to the Cytosorbents Medical Advisory Board. He is a highly respected researcher/pioneer in the announced that CAR T-cell cancer immunotherapy area, and from the University of Pennsylvania. In February 2014 Cytosorb announced that it was collaborating with the University of Pennsylvania's Vet school about cancer cachexia. http://www.marketwired.com/press-release/cytosorbents-university-pennsylvania-vet-school-collaborate-expand-cytosorbr-research-otcqb-ctso-1877114.htm.
You are misrepresenting what I stated. I have made more than my fair share of bad decisions, but if I don't believe in a companies management I would sell and go on to another company. I actually welcome anyone to criticize my investments, but truthful and constructive criticism. I cannot see any comparison at all with CTSO and your SIRI. My belief is that Cytosorbents is about to take off. We will be profitable soon, very little debt (due to Dr. Chan), are expanding to new territories and new indications, new products. Those are not excuses HTC, those are truths.
paulsby, I would absolutely not be in a company in which I didn't believe in the management....and you should not also. Dr. Chan has been a great custodian of the companies monies and worked with a small staff to move this company forward. Soon to be in the USA.
HTC, you are comparing apples to oranges as you short. Dr. Chan has led this OTC company to where it is meeting it's inflection point. Sales are doubling every year, new partners, new territories, new products, cash to last the company until it begins returning it's first profit within a year. All that with incredible margins.
paulsby, Dr. Chan has stated that we will break even within 1-2 years.
Why do you say that Fresenius and Biocon are not ramping up sales? That is simply not true. Revenue is growing at 100% per year. I believe that when Q12017 sales are announced we will have a substantial sales price jump, all other news has been nothing but good.
snow, the bottom line always matters. Recall though, that Dr. Chan stated that the company would be at the breakeven point within 1 to 2 years.
There has been nothing but positive information from CTSO. Sales are increasing 100% y over y, new territories coming online, new indications. This is a fantastic buying opportunity. I just added 2,521 shares.
The Herz und Diabeteszentrum, is a heart clinic in the German town Bad Oeynhausen. It is known for performing the most heart transplants in Europe. Wikipedia. It had 500 beds in 2010.
To be clear pearsby, you own no shares of CTSO, correct? Every bid that you have ever posted has been a low ball.
Dr. Chan has publicly stated that he will sell the fruit, but not the tree. Do not expect a buyout, but instead expect a steadily increasing share price as sales continue to double and then dividends several years after we reach profitability.
pearsby, stop misleading,you know that Dr. Chan does not want dilutive funding and on July 1, 2016 " CytoSorbents Corporation and its U.S. operating subsidiary, CytoSorbents Medical, Inc. entered into a Loan and Security Agreement with Bridge Bank, securing an initial $5 million 4-year term loan that was funded on June 30, 2016. Interest-only monthly payments are due for the first year and then monthly principal and interest payments are due through the remainder of the term. Prior to June 30, 2017, CytoSorbents has the ability, at its discretion, to receive an additional term loan of $5 million, provided certain conditions are met. If this occurs, the period of interest-only payments on both term loans will be extended by six months through January 31, 2018, followed by 30 months of straight line amortization through the July 1, 2020 maturity date.
Everyone read the entire article, what I read is that two out of three went home alive. Realistically, they all would have died without Cytosorb, so we saved 67%. Yes, I read that more testing is necessary. When that testing is complete one day, the share price will be $30 instead of $5.70.
I am going to ridicule you pearsby. CTSO has six consecutive record breaking quarters, it is staying on course to double sales every year. There are not many companies that are doing that. Certainly not more than a handful that are at 1,000% per year. With Terumo and the new expanded agreement with Fresenius, sales will ramp up even faster.
pearsby, in my opinion the entire ballgame has now changed for CTSO. We are receiving good news on top of good news and the price is climbing steadily. There will be more good news tomorrow and the quarterly report will be out within a month. You are still planning to buy in at $4.78 I presume?
Short squeeze? It could be.
CTSO decided not to go with the EAP, they are going for approval for Cardiac Surgery, not sepsis. They will go for sepsis approval when they have more revenue or when they have a partner to help pay. You lost your hiney of Spectral, so you know how that works. There is absolutely no worries about safety, you can rant on and mislead, but over 20,000 successful treatments. 20,000 successful treatments is a huge data lock. The FDA simply wants reliable, credible and valid large scale data for both efficacy and Safety, that is your one true statement. CTSO has shown the world safety, the efficacy is coming. That is exactly why newbies can buy CTSO at $5.70 per share now or wait for the data and pay $20.00 per share. ...You know this...but are baiting the susceptible Newbies. They should believe the adopting EU docs who have full approval and are increasing sales by new records each quarter.